Global Autoimmune Disease Therapeutics Market to Exceed US$77 Billion by 2017, According to New Report by Global Industry Analysts, Inc.

GIA announces the release of a comprehensive global report on Autoimmune Disease Therapeutics market. The global market for Autoimmune Disease Therapeutics is projected to exceed US$77 billion by the year 2017, driven by the rising incidence of autoimmune complications, growing adoption of biologics as the first line of therapy for autoimmune diseases, and extended labels of existing therapeutic drugs.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Autoimmune Disease Therapeutics: A Global Strategic Business Report

San Jose, CA (PRWEB) November 16, 2011

Follow us on LinkedIn - With the global incidence and prevalence of autoimmune diseases rising, the market for drugs used for the treatment of these diseases is expected to grow in the near future. Key factors driving this growth include increasing use of biologics, which command higher price than conventional drugs, and hence are major revenue earners for manufacturers. Besides, factors such as unmet medical needs and an extensive pipeline of drugs with superior efficacy keep growth prospects optimistic. Companies engaged in the development of new drugs continue to rely on superior efficacy, expansion of indications and convenient mode of drug administration for ensuring success of their products. On the other hand, manufacturers of currently marketed products are focusing on developing follow on products to retain their share in the market.

Biologics are increasingly being accepted as first line of treatment owing to their therapeutic capabilities in controlling and treatment of various autoimmune complications. These capabilities are in turn enabling pharmaceutical companies to begin label extensions for their current portfolio of biologics for multiple autoimmune problems. Humira, Enbrel, and Remicade are some of the biologics that are emerging as blockbuster drugs owing to their high efficacy profiles. Demand is also fuelled by the introduction of new products, enhanced access to drugs, and improved penetration of existing drugs. New products being launched in the market provide expanded therapeutic options for patients who fail to respond to existing therapies. These products are increasingly becoming popular as alternative to the conventional treatment options.

As stated by the new market research report on Autoimmune Disease Therapeutics, the US continues to remain the largest regional market. An aging US population and rising incidence of autoimmune diseases is driving the US market for biological therapies in the autoimmune disease therapeutic area. Though higher priced compared to conventional products, the biologics market is benefiting from the launch of novel biologics that offer superior efficacy over conventional therapeutic options. In addition, inclusion of self-administered drugs in Medicare Part D program enhanced market reach of these drugs. European market for autoimmune disease therapeutics is expected to grow at a compounded annual rate of 8.7% over the analysis period.

Rheumatoid Arthritis represents the largest segment in the global autoimmune disease therapeutics market. Growth in the rheumatoid arthritis therapeutics would be driven by an aging population and increasing incidence of autoimmune disorders. The demand for such therapeutics is enormous due to the high and unmet need for effective and safe agents with the ability to offer a new action mechanism. Growing at a compounded annual rate of 12% over the analysis period, Psoriasis drugs represents the fastest growing segment in the autoimmune disease therapeutics market. The global market for multiple sclerosis drugs would be driven by the high unmet need in the sector in terms of efficacy as well as safety.

Major players in the marketplace include Abbott Laboratories, Amgen Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bristol-Myers Squibb Company, Elan Corporation Plc, Eli Lilly and Company, F. Hoffmann-La Roche AG, Chugai Pharmaceutical Co. Ltd., Genentech Inc., GlaxoSmithKline Plc, Johnson & Johnson Inc., Merck & Co. Inc., Merck Serono SA, Novartis AG, Sanofi-aventis SA, Shire plc, Teva Pharmaceuticals Industries Limited, and UCB S.A.

The research report titled “Autoimmune Disease Therapeutics: A Global Strategic Business Report” announced by Global Industry Analysts, Inc., provides a comprehensive review of trends, issues, strategic industry activities, and profiles of major companies worldwide. The report provides market estimates and projections (US$ Million) for disease segments Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics), and Others, across geographic markets such as the US, Japan, Europe, and Rest of World.

For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Autoimmune_Disease_Therapeutics_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

###


Contact

Attachments